Cedar Mountain Advisors
AXSM icon

Cedar Mountain Advisors’s Axsome Therapeutics AXSM Stock Holding History

Cedar Mountain Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.2K Hold
66
– – ﹤0.01% 419
2026
Q2 		$16.2K Hold
66
– – ﹤0.01% 391
2026
Q1 		$11.2K Buy
+66
New +$11.4K ﹤0.01% 431

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
Washington Trust Advisors
Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Stanley-Laman Group
Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Cedar Mountain Advisors's AXSM Position: Q3 2026 in Review

Cedar Mountain Advisors held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 66 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Cedar Mountain Advisors first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $16.2K in Q2 2026. 57 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Cedar Mountain Advisors held 66 shares of Axsome Therapeutics worth $12.2K as of Q3 2026.
  • Cedar Mountain Advisors left its Axsome Therapeutics share count unchanged in Q3 2026.
  • Axsome Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #419 holding.
  • Cedar Mountain Advisors first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Cedar Mountain Advisors's Axsome Therapeutics position peaked at $16.2K in Q2 2026.
  • 57 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.